Another strong performance was achieved by the Asia/Pacific (APAC) region. At €332.6m, revenue was significantly higher than the prior-year figure of €278.7m – an increase of 19.3 percent (adjusted for currency effects: 17.3 percent). A large part of this growth is again attributable to the Chinese market, as well as Southeast Asia and India.
Revenue in the EMEA region declined slightly by 1.1 percent in the first nine months of 2016/17 (adjusted for currency effects: -0.4 percent). Revenue came in at €259.6m (prior year: €262.5m). The development of business was particularly below average in the United Kingdom, Southern Europe and the Middle East.
Revenue in the Americas region increased by a further 5.9 percent (adjusted for currency effects: 3.7 percent), to €272.5m (prior year: €257.3m).
Earnings per share (EPS) increased significantly year-on-year, to €1.10 (prior year: €0.83). Besides the increase in the operating profit, this was also attributable to gains on currency hedges, compared with losses in the same period of the prior year. Carl Zeiss Meditec confirms its forecast revenue target of €1,150m to €1,200m for fiscal year 2016/17. The EBIT margin is expected to be within the range also forecast for the medium term, of 13 to 15 percent.